SEC Form 4 · accession 0001209191-15-086853
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sander A Flaum
Director
Period of report
Mar 20, 2015
Accepted (ET)
Dec 23, 2015 · 4:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 20, 2015 | S | 9,800 | $42.00 | D | 19,599 | D | |
| Common StockF2 | Dec 22, 2015 | S | 3,225 | $93.755 | D | 16,374 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold pursuant to a prospectus filed on March 17, 2015 with the Securities and Exchange Commission.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $93.73 to $93.7563, inclusive. The reporting person undertakes to provide to Eagle Pharmaceuticals, Inc., any security holder of Eagle Pharmaceuticals, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.